How to optimize and overcome challenges in in vitro oncology models
03 Feb 2022
The challenges we are facing in cancer research are complex. From drug discovery to clinical diagnostics and disease prevention, the oncology field continues its mission to overcome many difficult setbacks to accelerate research and improve the lives of patients affected by cancer. Thanks to this research and associated technological advances, survival rates have expanded, the quality of lives has improved, and breakthroughs have been made.
In this virtual roundtable discussion, we will be asking leading oncology experts to:
- Share their advice and expertise on how to optimize and overcome key challenges associated with in vitro oncology models
- Reveal the complexities of cancer progression
- Detail the performance of immunotherapy in a murine model with chronic inflammation
- Highlight the challenges that pre-existent autoimmune landscapes impose to immunotherapy
- Explain traditional cloning in organoid culture using CRISPR/CAS9 editing
- Explore how to improve primary organoid culture conditions to successfully grow desired cell types and support organoid growth and selection after gene editing
- Explain more on developing the latest patient-derived 3D cancer cell cultures for use in precision medicine
Dr. Laura Martin, ex vivo models director, Englander Institute for Precision Medicine (EIPM)
Dr. Julio Valencia, staff scientist, The National Cancer Institute
Dr. Mahnaz Darvish Damavandi, postdoctoral research associate, Nuffield Department of Surgical Science, University of Oxford
Hilary Sherman, senior scientist, Corning Life Sciences Applications Lab
Who should attend?
Researchers working within oncology research. This webinar will be particularly valuable for those working directly with in vitro oncology models.
Corning Life Sciences